Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary CYP27B1 for treatment and prevention

Journal of Steroid Biochemistry and Molecular Biology

Volumn 136, Issue 1, 2013, Pages 289-295

  Krishnan, Aruna V ^a   Swami, Srilatha ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Calitriol; CYP27B1; Mouse; Prevention

Indexed keywords

CALCITRIOL; COLECALCIFEROL; MESSENGER RNA; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; CALCIUM METABOLISM; CANCER GROWTH; CANCER RISK; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG SAFETY; ENDOCRINE FUNCTION; ESTROGEN SYNTHESIS; HAPLOINSUFFICIENCY; HUMAN; HYPERCALCEMIA; IONIZING RADIATION; META ANALYSIS (TOPIC); NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ANIMALIA; MUS;

EID: 84881139319     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.08.005     Document Type: Review

References (62)

1. D. Feldman, P.J. Malloy, A.V. Krishnan, E. Balint, Vitamin D: biology, action and clinical implications, in: R. Marcus, D. Feldman, D.A. Nelson, C.J. Rosen (Eds.), Osteoporosis, vol. 1, third edition, Elsevier Academic Press, San Diego, 2007, pp. 317-382.
2. T.M. Beer, A. Myrthue, Calcitriol in cancer treatment: from the lab to the clinic, Molecular Cancer Therapeutics 3 (3) (2004) 373-381.
3. K.W. Colston, C.M. Hansen, Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer, Endocrine-Related Cancer 9 (1) (2002) 45-59.
4. K.K. Deeb, D.L. Trump, C.S. Johnson, Vitamin D signalling pathways in cancer: potential for anticancer therapeutics, Nature Reviews Cancer 7 (9) (2007) 684-700.
5. A.V. Krishnan, D. Feldman, Mechanisms of the anti-cancer and antiinflammatory actions of vitamin D, Annual Review of Pharmacology and Toxicology 51 (2011) 311-336.
6. A.V. Krishnan, D.L. Trump, C.S. Johnson, D. Feldman, The role of vitamin D in cancer prevention and treatment, Endocrinology and Metabolism Clinics of North America 39 (2) (2010) 401-418.
7. Q.T. Luong, H.P. Koeffler, Vitamin D compounds in leukemia, The Journal of Steroid Biochemistry and Molecular Biology 97 (1-2) (2005) 195-202.
8. F. Pereira, M.J. Larriba, A. Munoz, Vitamin D and colon cancer, Endocrine-Related Cancer 19 (3) (2012) R51-R71.
9. J. Welsh, Vitamin D metabolism in mammary gland and breast cancer, Molecular and Cellular Endocrinology 347 (1-2) (2011) 55-60.
10. P. Chen, P. Hu, D. Xie, Y. Qin, F. Wang, H. Wang, Meta-analysis of vitamin D, calcium and the prevention of breast cancer, Breast Cancer Research and Treatment 121 (2) (2010) 469-477.
11. L. Yin, N. Grandi, E. Raum, U. Haug, V. Arndt, H. Brenner, Meta-analysis: serum vitamin D and breast cancer risk, European Journal of Cancer 46 (12) (2010) 2196-2205.
12. C.F. Garland, E.D. Gorham, S.B. Mohr, W.B. Grant, E.L. Giovannucci, M. Lipkin, H. Newmark, M.F. Holick, F.C. Garland, Vitamin D and prevention of breast cancer: pooled analysis, The Journal of Steroid Biochemistry and Molecular Biology 103 (3-5) (2007) 708-711.
13. Institute of Medicine, Dietary Reference Intakes for Calcium and Vitamin D, The National Academic Press, Washington, DC, 2011.
14. C.J. Rosen, J.S. Adams, D.D. Bikle, D.M. Black, M.B. Demay, J.E. Manson, M.H. Murad, C.S. Kovacs, The nonskeletal effects of vitamin D: an endocrine society scientific statement, Endocrine Reviews 33 (3) (2012) 456-492.
15. K. Townsend, C.M. Banwell, M. Guy, K.W. Colston, J.L. Mansi, P.M. Stewart, M.J. Campbell, M. Hewison, Autocrine metabolism of vitamin D in normal and malignant breast tissue, Clinical Cancer Research 11 (9) (2005) 3579-3586.
16. F.S. Fan, W.C. Yu, 1,25-Dihydroxyvitamin D3 suppresses cell growth DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line, Cancer Investigation 13 (3) (1995) 280-286.
17. S.S. Jensen, M.W. Madsen, J. Lukas, L. Binderup, J. Bartek, Inhibitory effects of 1alpha 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery, Molecular Endocrinology 15 (8) (2001) 1370-1380.
18. M. Simboli-Campbell, C.J. Narvaez, K. van Weelden, M. Tenniswood, J. Welsh, Comparative effects of 1 25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells, Breast Cancer Research and Treatment 42 (1) (1997) 31-41.
19. C.J. Narvaez, G. Zinser, J. Welsh, Functions of 1alpha,25- dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer, Steroids 66 (3-5) (2001) 301-308.
20. G. Pirianov, K.W. Colston, Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis, Molecular and Cellular Endocrinology 172 (1-2) (2001) 69-78.
21. G. Lazzaro, A. Agadir, W. Qing, M. Poria, R.R. Mehta, R.M. Moriarty, T.K. Das Gupta, X.K. Zhang, R.G. Mehta, Induction of differentiation by 1alphahydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors, European Journal of Cancer 36 (6) (2000) 780-786.
22. N. Pendas-Franco, J.M. Gonzalez-Sancho, Y. Suarez, O. Aguilera, A. Steinmeyer, C. Gamallo, M.T. Berciano, M. Lafarga, A. Munoz, Vitamin D regulates the phenotype of human breast cancer cells, Differentiation 75 (3) (2007) 193-207.
23. Q. Wang, D. Lee, V. Sysounthone, R.A.S. Chandraratna, S. Christakos, R. Korah, R. Wieder, 1,25-Dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects, Breast Cancer Research and Treatment 67 (2) (2001) 157-168.
24. L. Flanagan, K. Packman, B. Juba, S. O'Neill, M. Tenniswood, J. Welsh, Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion, The Journal of Steroid Biochemistry and Molecular Biology 84 (2-3) (2003) 181-192.
25. C.M. Hansen, T.L. Frandsen, N. Brunner, L. Binderup, 1alpha 25- Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro, Clinical & Experimental Metastasis 12 (3) (1994) 195-202.
26. K. Koli, J. Keski-Oja, 1alpha 25-Dihydroxyvitamin D3 and its analogues downregulate cell invasion-associated proteases in cultured malignant cells, Cell Growth and Differentiation 11 (4) (2000) 221-229.
27. J. Welsh, Vitamin D actions in mammary gland and breast cancer, in: D. Feldman, J.W. Pike, J.S. Adams (Eds.), Vitamin D, vol. 2, third edition, Elsevier Academic Press, San Diego, 2011, pp. 1657-1673.
28. A.V. Krishnan, S. Swami, D. Feldman, Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling, The Journal of Steroid Biochemistry and Molecular Biology 121 (1-2) (2010) 343-348.
29. A.V. Krishnan, S. Swami, L. Peng, J. Wang, J. Moreno, D. Feldman, Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy, Endocrinology 151 (1) (2010) 32-42.
30. S.Y. James, A.G. Mackay, L. Binderup, K.W. Colston, Effects of a new synthetic vitamin D analogue, EB1089 on the oestrogen-responsive growth of human breast cancer cells, Journal of Endocrinology 141 (3) (1994) 555-563.
31. A. Stoica, M. Saceda, A. Fakhro, H.B. Solomon, B.D. Fenster, M.B. Martin, Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells, Journal of Cellular Biochemistry 75 (4) (1999) 640-651.
32. S. Swami, A.V. Krishnan, D. Feldman, 1alpha,25-Dihydroxyvitamin D3 downregulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells, Clinical Cancer Research 6 (8) (2000) 3371-3379.
33. S. Swami, A.V. Krishnan, J.Y. Wang, K. Jensen, L. Peng, M.A. Albertelli, D. Feldman, Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo, Hormones and Cancer 2 (3) (2011) 190-202.
34. K. VanWeelden, L. Flanagan, L. Binderup, M. Tenniswood, J. Welsh, Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089, Endocrinology 139 (4) (1998) 2102-2110.
35. H.J. Lee, S. Paul, N. Atalla, P.E. Thomas, X. Lin, I. Yang, B. Buckley, G. Lu, X. Zheng, Y.R. Lou, A.H. Conney, H. Maehr, L. Adorini, M. Uskokovic, N. Suh, Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity, Cancer Prevention Research 1 (6) (2008) 476-484.
36. J.Y. So, H.J. Lee, A.K. Smolarek, S. Paul, C.X. Wang, H. Maehr, M. Uskokovic, X. Zheng, A.H. Conney, L. Cai, F. Liu, N. Suh, A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer, Molecular Pharmacology 79 (3) (2011) 360-367.
37. K. Koshizuka, T. Kubota, J. Said, M. Koike, L. Binderup, M. Uskokovic, H.P. Koeffler, Combination therapy of a vitamin D3 analog and all-trans-retinoic acid: effect on human breast cancer in nude mice, Anticancer Research 19 (1A) (1999) 519-524.
38. K. Koshizuka, M. Koike, H. Asou, S.K. Cho, T. Stephen, R.K. Rude, L. Binderup, M. Uskokovic, H.P. Koeffler, Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo, Breast Cancer Research and Treatment 53 (2) (1999) 113-120.
39. S. Sundaram, A. Sea, S. Feldman, R. Strawbridge, P.J. Hoopes, E. Demidenko, L. Binderup, D.A. Gewirtz, The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice, Clinical Cancer Research 9 (6) (2003) 2350-2356.
40. L.L. Ooi, Y. Zheng, H. Zhou, T. Trivedi, A.D. Conigrave, M.J. Seibel, C.R. Dunstan, Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis, Bone 47 (4) (2010) 795-803.
41. L.L. Ooi, H. Zhou, R. Kalak, Y. Zheng, A.D. Conigrave, M.J. Seibel, C.R. Dunstan, Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis, Cancer Research 70 (5) (2010) 1835-1844.
42. M.A. Anzano, J.M. Smith, M.R. Uskokovic, C.W. Peer, L.T. Mullen, J.J. Letterio, M.C. Welsh, M.W. Shrader, D.L. Logsdon, C.L. Driver, et al., 1 alpha, 25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat, Cancer Research 54 (7) (1994) 1653-1656.
43. K.W. Colston, G. Pirianov, E. Bramm, K.J. Hamberg, L. Binderup, Effects of seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors, Breast Cancer Research and Treatment 80 (3) (2003) 303-311.
44. S.Y. James, E. Mercer, M. Brady, L. Binderup, K.W. Colston, EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro, British Journal of Pharmacology 125 (5) (1998) 953-962.
45. G. Murillo, R.G. Mehta, Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5, The Journal of Steroid Biochemistry and Molecular Biology 97 (1-2) (2005) 129-136.
46. M.P. Cleary, M.E. Grossmann, A. Ray, Effect of obesity on breast cancer development, Veterinary Pathology 47 (2) (2010) 202-213.
47. G.M. Zinser, J. Welsh, Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice, Carcinogenesis 25 (12) (2004) 2361-2372.
48. D. Matthews, E. LaPorta, G.M. Zinser, C.J. Narvaez, J. Welsh, Genomic vitamin D signaling in breast cancer: insights from animal models and human cells, The Journal of Steroid Biochemistry and Molecular Biology 121 (1-2) (2010) 362-367.
49. E.L. Milliken, X. Zhang, C. Flask, J.L. Duerk, P.N. MacDonald, R.A. Keri, EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer, Cancer Letters 229 (2) (2005) 205-215.
50. M. Hewison, J.S. Adams, Extrarenal 1a-hydroxylase, in: D. Feldman, J.W. Pike, J.S. Adams (Eds.), Vitamin D, vol. 1, Elsevier Academic Press, San Diego, 2011, pp. 777-804.
51. C.M. Kemmis, S.M. Salvador, K.M. Smith, J. Welsh, Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3, Journal of Nutrition 136 (4) (2006) 887-892.
52. S. Ching, S. Kashinkunti, M.D. Niehaus, G.M. Zinser, Mammary adipocytes bioactivate 25-hydroxyvitamin D(3) and signal via vitamin D(3) receptor, modulating mammary epithelial cell growth, Journal of Cellular Biochemistry 112 (11) (2011) 3393-3405.
53. R.J. Skowronski, D.M. Peehl, D. Feldman, Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3, Endocrinology 136 (1) (1995) 20-26.
54. W.R. Wecksler, W.H. Okamura, A.W. Norman, Studies on the mode of action of vitamin D-XIV. Quantitative assessment of the structural requirements for the interaction of 1 alpha, 25-dihydroxyvitamin D3 with its chick intestinal mucosa receptor system, Journal of Steroid Biochemistry 9 (10) (1978) 929-937.
55. M.J. Rowling, C. Gliniak, J. Welsh, J.C. Fleet, High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice, Journal of Nutrition 137 (12) (2007) 2608-2615.
56. M.V. Young, G.G. Schwartz, L. Wang, D.P. Jamieson, L.W. Whitlatch, J.N. Flanagan, B.L. Lokeshwar, M.F. Holick, T.C. Chen, The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D, Carcinogenesis 25 (6) (2004) 967-971.
57. S. Swami, A.V. Krishnan, J.Y. Wang, K. Jensen, R. Horst, M.A. Albertelli, D. Feldman, Dietary vitamin D3 and 1,25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer, Endocrinology 153 (6) (2012) 2576-2587.
58. A. Murayama, M.S. Kim, J. Yanagisawa, K. Takeyama, S. Kato, Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching, EMBO Journal 23 (7) (2004) 1598-1608.
59. M.M. Turunen, T.W. Dunlop, C. Carlberg, S. Vaisanen, Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene, Nucleic Acids Research 35 (8) (2007) 2734-2747.
60. X. Peng, M. Hawthorne, A. Vaishnav, R. St-Arnaud, R.G. Mehta, 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture, Breast Cancer Research and Treatment 113 (1) (2009) 31-41.
61. J.R. Muindi, R.A. Modzelewski, Y. Peng, D.L. Trump, C.S. Johnson, Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses, Oncology 66 (1) (2004) 62-66.
62. J.C. Fleet, C. Gliniak, Z. Zhang, Y. Xue, K.B. Smith, R. McCreedy, S.A. Adedokun, Serum metabolite profiles and target tissue gene expression define the effect of cholecalciferol intake on calcium metabolism in rats and mice, Journal of Nutrition 138 (6) (2008) 1114-1120.